Saliva contains a complex mixture of proteins and peptides as well as fragments derived from these molecules. By RP 1 -HPLC-ESI-MS analysis of the acidic soluble fraction of human whole saliva we have identified in the chromatographic pattern more than 120 different proteins and naturally occurring peptides (1-6). Their characterization was performed by a variety of mass spectrometric techniques coupled with different enzymatic treatments and amino acid sequencing. The proteins and naturally occurring peptides belong to families of well characterized salivary proteins including Histatins, Statherin, acidic and basic proline-rich proteins (aPRP and bPRP), Cystatins, and Defensins (1-6). Two-dimensional gel electrophoresis has also been used by other researchers for analysis of salivary proteins and peptides, but this technique is not well suited for identification of small peptides as illustrated by the difficulty in identifying Histatins and the majority of bPRPs and bPRP fragments (7-9). However, knowledge of salivary proteins and peptides as well as their naturally occurFrom the ‡Dipartimento di Scienze Applicate ai Biosistemi, Università di Cagliari,
Saliva contains a complex mixture of proteins and peptides as well as fragments derived from these molecules. By RP 1 -HPLC-ESI-MS analysis of the acidic soluble fraction of human whole saliva we have identified in the chromatographic pattern more than 120 different proteins and naturally occurring peptides (1) (2) (3) (4) (5) (6) . Their characterization was performed by a variety of mass spectrometric techniques coupled with different enzymatic treatments and amino acid sequencing. The proteins and naturally occurring peptides belong to families of well characterized salivary proteins including Histatins, Statherin, acidic and basic proline-rich proteins (aPRP and bPRP), Cystatins, and Defensins (1-6). Two-dimensional gel electrophoresis has also been used by other researchers for analysis of salivary proteins and peptides, but this technique is not well suited for identification of small peptides as illustrated by the difficulty in identifying Histatins and the majority of bPRPs and bPRP fragments (7) (8) (9) . However, knowledge of salivary proteins and peptides as well as their naturally occur-ring fragments is important to understand the various stages of maturation occurring during their secretion pathway (10, 11) .
Saliva originates from three pairs of major glands (parotid, submandibular, and sublingual) with a small fluid contribution from several minor glands (12) . Most salivary proteins are synthesized in the acinar cells of the glands and follow a well defined secretory pathway that for many proteins includes transit in the Golgi apparatus and storage in secretory granules preceding their release from the cell into the duct system and secretion into the mouth (13) . During the transit in the cells the salivary proteins are subjected to a number of changes including removal of the signal peptide as well as various post-translational modifications (PTMs) such as proteolytic cleavage, glycosylation, phosphorylation, and sulfation. Further modifications of the proteins and peptides occur in ducts and in the oral cavity after secretion from the cells as a result of a number of proteolytic enzymes of different origin.
This study describes the comparative profiling of intact proteins and naturally occurring peptides of cellular fractions enriched in secretory granules (enriched granule preparations (EGPs)) as well as parotid (Pr), submandibular/sublingual (Sm/ Sl), and whole saliva by the above cited RP-HPLC-ESI-MS methods (1) (2) (3) (4) (5) (6) . The results provide information useful for a better understanding of the spatial and temporal relationships of the modifications the proteins undergo from their synthesis on the ribosomes to their isolation from whole saliva. In fact, these analyses allow a comparison of the events taking place during synthesis and secretion from Pr and Sm/Sl glands and make it possible to distinguish between events occurring prior to storage in secretory granules, those taking place between granule release and secretion into the mouth, and those occurring after secretion into the mouth (Fig. 1 ).
MATERIALS AND METHODS
Reagents and Instrumentation-All general chemicals and reagents were of analytical grade and were purchased from Farmitalia-Carlo Erba (Milan, Italy), Merck, and Sigma-Aldrich.
For HPLC-ESI-MS a ThermoFinnigan (San Jose, CA) apparatus was used. The Surveyor HPLC system was equipped with a photodiode array detector and connected by a T splitter to the electrospray ionization/ion trap mass spectrometer, LCQ Deca XP Plus (ThermoFinnigan). The chromatographic column was a Vydac (Hesperia, CA) C 8 with 5-m particle diameter (column dimensions 150 ϫ 2.1 mm).
Mass values of some peptides were confirmed by MALDI-TOF mass spectrometry performed on a Bruker Daltonics Autoflex apparatus (Bremen, Germany). Peptide sequencing was carried out with a Procise 610A Protein Sequencer (Applied Biosystems, Foster City, CA).
Sample Collection and Treatment-Resting whole saliva was collected from normal adult volunteers between 2 and 4 p.m. using a soft plastic aspirator. Parotid saliva was collected by a Lashley cup (14) , and submandibular/sublingual saliva was obtained by means of an appliance described by Truelove et al. (15) . Flow of glandular saliva was stimulated by sucking on sour lemon candy. An acidic solution (0.2% TFA) was added to the salivary samples exactly in 1:1 (v/v) ratio at 4°C immediately after collection, and the solution was centrifuged at 8000 ϫ g for 5 min (4°C). The acidic supernatant was separated from the precipitate, and the supernatant was either immediately analyzed by HPLC-MS apparatus or stored at Ϫ80°C. Parotid and submandibular gland specimens were biopsies from patients undergoing removal of salivary gland neoplasia. The experimental protocol was approved by the Ethics Committee of the Faculty of Medicine of the Catholic University. Pieces of surgically removed glands considered eligible on the basis of their normal histological appearance assessed by extemporaneous histopathological analysis were used to obtain enriched secretory granule preparations. The pieces obtained were immediately used to make enriched granule preparations.
Preparation of Salivary Granules and Their Extracts-Granules were isolated according to the procedure of Borges-Silva and Bento-Alves (16) with some modifications. The salivary gland was washed with 0.9% NaCl aqueous solution to eliminate blood, minced into small pieces by using a scalpel, and then homogenized in a glass PotterElvehjem homogenizer with a Teflon pestle as a 5% (w/v) suspension in 340 mM sucrose, 0.5 mM EDTA, 10 mM HEPES, pH 7.4, at room temperature. To remove fibrous connective tissue and insoluble particles, the homogenate was filtered through four layers of clean coarse gauze in the homogenizing medium and then centrifuged at 500 ϫ g for 10 min at 4°C. The supernatant was submitted to further centrifugation at 2500 ϫ g for 15 min at 4°C, and the pellet, corresponding to the crude fraction of secretory granules as verified by scanning electron microscopy (S4000 FEG scanning electron microscope, Hitachi, Tokyo, Japan), was solubilized in 700 l of 0.2% TFA. The granule fraction was centrifuged at 8000 ϫ g for 10 min, and CHCl 3 was added to the supernatant (1:1, v/v) to remove lipidic components. The aqueous phase was directly used for RP-HPLC-ESI ion trap MS analyses or stored at Ϫ80°C.
HPLC-ESI-MS and MALDI-TOF-MS Experiments-Proteins
(Cystatins, aPRPs, bPRPs, Histatins, Statherin, and P-B peptide) and naturally occurring peptides derived from aPRPs, bPRPs, Histatins, Statherin, and P-B peptide were already identified in previous studies (1) (2) (3) (4) (5) (6) . Identification was carried out by ESI ion trap MS and MALDI-TOF-MS coupled with different enzymatic treatments (trypsin, chymotrypsin, proteinase K, proteinase V8, Pronase, carboxy-and aminopeptidases, and phosphatase), chemical treatments (acidic hydrolysis for sulfoderivatives), and automated amino acid sequencing, the latter on some purified intact proteins and naturally occurring peptides as well as on some of their proteolytic fragments. Separation of proteins and naturally occurring peptides was performed using RP-HPLC-ESI mass spectrometry. The following solutions were utilized for the reversed phase chromatography: 0.056% (v/v) aqueous TFA (eluent A) and 0.05% (v/v) TFA in acetonitrile-water 80:20 (eluent B). The proteins were eluted using a linear gradient from 0 to 55% FIG. 1. Schematic presentation of the secretion pathway of salivary peptides showing the ability of the different sample types to reveal PTM localization. ER, endoplasmic reticulum; GS, secreted glandular saliva (parotid or submandibular/sublingual saliva); NL, normalization level; ␣-def, ␣-defensins 1-4. eluent B in 40 min at a flow rate of 0.30 ml/min. A T splitter addressed a flow rate of 0.20 ml/min toward the diode array detector and a flow rate of 0.10 ml/min toward the ESI source. Usually during the first 5 min of RP-HPLC separation the eluate was not addressed toward the ion trap MS apparatus to avoid instrument damage as a result of the high salt content. Mass spectra, in the positive ion mode, were collected every 3 ms. MS spray voltage was 4.50 kV, and the capillary temperature was 220°C.
The structure of some bPRP fragments not previously characterized was confirmed by MS/MS analyses, generally carried out contemporaneously on different charged ions. MS/MS experiments were performed by detecting parent ions with a peak width of 2-4 m/z value and at 40% of the maximum activation amplitude with activation q ϭ 0. 25 and an activation time of 30 ms.
For MALDI-TOF-MS analysis samples were dissolved in 0.1% aqueous TFA, and the solution was treated with a C 18 ZipTip micropipette to remove salts. The desalted solution was mixed 1:1 (v/v) with a solution of ␣-cyano-4-hydroxycinnamic acid prepared in acetonitrile/water (50:50, v/v) containing 0.1% TFA. Aliquots of 1 l of the mixture were spotted onto the stainless steel target of the MALDI instrument. The calibration was performed using peptide calibration standards (angiotensins I and II, substance P, and bombesin; m/z range, 1000 -3150 Da). Positive and negative MALDI spectra were acquired in either linear or reflectron mode with a pulsed nitrogen laser (337 nm). In linear mode an acceleration voltage of 20 kV, a detector gain voltage of 1300 V, a pulsed ion extraction time of 350 ns, and a laser frequency of 5 Hz were applied. In the reflectron mode an acceleration voltage of 19 kV, a detector gain voltage of 1400 V, a pulsed ion extraction time of 150 ns, and a laser frequency of 5 Hz were applied. Mass spectra were acquired over the mass range of 700 -6000 Da with the low mass cutoff of 500 Da, and 400 scans were averaged for each spectrum.
Data Analysis and Determination of Relative Abundances-Deconvolution of averaged ESI-MS spectra was automatically performed either by using the Bioworks Browser software provided with the Deca XP instrument or by MagTran 1.0 software (17) . As previously made for the identification of some small naturally occurring fragments derived from Histatins (4), bPRP (and aPRP) fragments not previously identified were characterized by manual comparison of their experimental MS/MS spectra with the theoretical spectra generated using the MS-Product program available with ProteinProspector. The sequences used to generate theoretical mass spectra were all those originating from the cleavage of known acidic and basic PRPs as suggested by the ExPASy FindPept program with a mass tolerance of Ϯ0.5 Da, with and without phosphorylation, and with no specific enzymatic cleavage. A peptide match was considered positive when all the experimental m/z values with a relative abundance higher than 10% were present in the theoretical fragmentation spectrum and when the differences between the experimental and theoretical values were less than Ϯ0.2 m/z.
An extracted ion current (XIC) strategy was used to selectively reveal salivary peptides described in this study. The m/z values used in the multiple XIC strategy were carefully selected to exclude values common to other closely eluting proteins (Ϯ0.5 m/z). The area of the XIC peaks, measured when the signal to noise ratio was at least 5, was used for semiquantitative estimation of relative peptide/protein abundances. For Statherin, P-B peptide, and major Histatins (Histatins 1, 3, 5, and 6) UV peak area at 278 nm was also measured.
Samples Analyzed-Informed consent was obtained from all the subjects involved. To undertake a comparative analysis as outlined in Fig. 1 , samples were obtained from 10 healthy adult volunteers (five females, five males, 26 -55 years old) of Pr, Sm/Sl, and whole saliva (WS). Because of the origin of the samples statistical analysis was performed utilizing paired tests. Flow rates of Pr and Sm/Sl measured during the sampling varied between subjects (from 0.1 to 0.3 ml/min) but was similar in the same subject.
Ten samples of EGPs from parotid glands were analyzed (five females, five males, 27-76 years old). For three of these samples (one female, two males, 57-60 years old) it was possible to compare the results with WS obtained from the same subjects. Three samples of EGPs from submandibular gland were also examined (one female, two males, 40 -65 years old). For one sample (female, 58 years old) it was possible to compare the results with WS from the same subject.
RESULTS
Analysis of the RP-HPLC-ESI-MS profiles of whole saliva, parotid, and Sm/Sl secretions and parotid and submandibular EGPs (Fig. 2) allowed determination of the relative abundance of any peptide and protein belonging to the families of aPRPs, bPRPs, Histatins, Statherin, P-B peptide, and salivary Cystatins. The results are reported in Tables I, II , and IV-VIII. From a comparison of the composition of parotid and Sm EGPs, parotid and Sm/Sl secretions, and whole saliva it was possible to locate various postsynthetic modifications of parotid and Sm/Sl proteins as outlined in Fig. 1 . A comparative analysis of parotid and Sm/Sl saliva provided information about differences in secretion from the glands.
aPRPs-The aPRP complex is expressed by two loci named PRH1 (three common alleles: PIF, Db, and Pa) and PRH2 (two common alleles: PRP1 and PRP2) localized close to each other on chromosome 12p13. The products of alleles commonly found in Caucasians together with their post-translational cleavage products are schematically illustrated in Fig.  3 . More detailed information can be found in a previous study (3) , in the literature therein reported, and in the Swiss-Prot database (accession number P02810). The masses of the different isoforms, their frequency of occurrence in the granule and saliva preparations, and their concentration as determined semiquantitatively are reported in Table I . It is worthwhile to observe that the masses may differ by as little as 1 Da (e.g. PRP1 and PRP2). All the aPRP isoforms have a pyroglutamic N-terminal residue and are diphosphorylated on Ser 8 and Ser 22 as shown in earlier studies (18) . However, minor amounts of triphosphorylated isoforms (Ser 8 , Ser 17 , and Ser 22 ) as well as mono-and non-phosphorylated derivatives are present in whole saliva as observed previously (3). Four isoforms (PRP1, PRP2, PIF-s, and Db-s) are partially cleaved at the RPPR2 sequence (residue 106 in PRP1, PRP2, and PIF-s; residue 127 in Db-s) generating the PRP3, PRP4, PIF-f, and Db-f truncated isoforms, respectively, and the 44-residue P-C peptide common to all the isoforms. The Pa isoform is not prone to the convertase cleavage presumably due to an Arg 3 Cys substitution at residue 103 (19) . It is almost completely present in whole human saliva as a Pa dimer, with a mass value of 30,922 Ϯ 3 Da, generated by the formation of a disulfide bridge. Finally a carboxypeptidase activity generates small amounts of isoforms lacking the C-terminal residues (Fig. 3 ).
In agreement with previous studies the results of this study indicated that all the aPRPs were secreted both from Pr and Sm/Sl glands (Table I) . In fact, analysis of subjects carrying Pa and Db phenotypes revealed their presence in Sm/Sl. The circles in Table I (as well as in Tables II and IV -VIII) represent the approximate relative abundance determined for the different isoforms, fragments and derivatives (four closed circles, Ͼ45%; three closed circles, 30 -45%; two closed circles, 15-30%; one closed circle, 2-15%; one open circle, traces (Ͻ2%)). The detection frequencies (on the total number of samples) are reported in parentheses.
Due to the sporadic detection of Pa and Db phenotypes, we carried out comparative analyses of aPRP phosphorylation level and of relative abundance of the truncated isoforms only on PRP1 type isoforms (PIF-s, PRP1, and PRP2) (Fig. 3 ). There were no significant differences in the relative abundances of differently phosphorylated isoforms and in the ratios of entire and truncated isoforms in EGP, parotid, Sm/Sl, and whole saliva. These data indicated that both phosphorylation and proteolytic cleavage occur before sequestration into secretory granules in agreement with previous observations (20) .
Small percentages of non-phosphorylated truncated isoforms and triphosphorylated entire isoforms are usually detectable. In this respect, the different groups under analysis did not show significant differences.
Furthermore we were able to detect in one sample of whole saliva a small relative abundance of the pentaphosphorylated Pa dimer (average M r , 31,002 Ϯ 3) that derived from the dimerization of diphosphorylated and triphosphorylated Pa monomers. Interestingly EGP from the parotid gland of three subjects carrying the Pa phenotype showed high amounts of Pa monomer (about 40% of total Pa), whereas the monomer was almost undetectable both in parotid and whole saliva samples suggesting that dimerization occurs during granule maturation.
aPRP derivatives missing the C-terminal residue (desGln 150 and des-Arg 106 ) (Table I) were detected in a few granule and saliva samples and always in very small relative abundance (Ͻ2%) ( Table I) . As a consequence, the localization of aPRP C-terminal removal by carboxypeptidase action cannot be conclusively established from these data.
Paired comparison of parotid and Sm/Sl secretions showed that the phosphorylation level was significantly higher in parotid saliva for both PRP1 (PIF-s, PRP1, and PRP2) and PRP3 (PIF-f, PRP3, and PRP4) (Fig. 3) isoforms. Phosphorylation levels were calculated from the XIC peak area of the different phosphorylated forms considering the number of phosphate groups by the following ratio: ratio ϭ 100 ϫ (monophos.)/ (monophos. ϩ 2 ϫ (diphos.) ϩ 3 ϫ (triphos.)).
The statistical analysis (paired t test) gave the following results: PRP1 type isoforms (n ϭ 10): parotid ϭ 4.2 Ϯ 1.7 (mean Ϯ S.D.), Sm/Sl ϭ 7.7 Ϯ 2.4 (mean Ϯ S.D.), p Ͻ 0.00002; PRP3 type isoforms (n ϭ 10): parotid ϭ 3.9 Ϯ 1.5 (mean Ϯ S.D.), Sm/Sl ϭ 8.8 Ϯ 3.0 (mean Ϯ S.D.), p Ͻ 0.0002. These results indicated that the kinase involved in aPRP phosphorylation is more active in parotid gland.
Parotid and Sm/Sl secretions showed another interesting and very significant difference in the relative abundance of all the truncated PRP3 isoforms compared with the total sum of aPRPs (PRP1 ϩ PRP3): ratio ϭ 100 ϫ (total PRP3)/(total PRP3 ϩ total PRP1). The statistical analysis gave the following results (n ϭ 10): parotid ϭ 25.6 Ϯ 8.7 (mean Ϯ S.D.), Sm/Sl ϭ 35.4 Ϯ 8.6 (mean Ϯ S.D.), p Ͻ 0.0002 (paired t test). The higher percentages of truncated PRP3 type isoforms indicated a higher activity of convertase cleavage of aPRP in Sm/Sl gland than parotid gland. The validity of the use of the XIC peak areas for semiquantitative evaluations of the relative abundances of different peptides and fragments is supported by an examination of 42 Db-f monophos. whole saliva samples obtained from PIF homozygotic subjects. There was a highly significant linear correlation (r ϭ 0.970) of the XIC peak areas of the P-C peptide and PRP3 type truncated isoforms as would be expected for products originating by cleavage of a common parent protein.
As expected, paired analysis of whole saliva consistently showed relative abundances between those of parotid and Sm/Sl glands. bPRPs-bPRPs constitute the most complex family of salivary proteins both in terms of genetic variability and PTMs. Four loci, named PRB1-4, clustered on chromosome 12p13.2 near the aPRP loci are responsible for their synthesis (21) . Each locus comprises at least three alleles, named S (small), M (medium), and L (large). A fourth allele, VL (very large), was described for PRB-1 and PRB-3 loci (22) (23) (24) (25) . Fig. 4 summarizes the present knowledge of bPRP loci including coding regions for the various secreted proteins. The sequences of the majority of b-PRPs are similar and highly repetitive (26) . After loss of the signal peptide, all proproteins are submitted to multiple cleavages, phosphorylation, glycosylation, and Cterminal removal (5, 27, 28) . In contrast to aPRPs, uncleaved proproteins of bPRPs are not detectable in saliva. A preliminary proteomics study of bPRPs has been published (5) . with earlier investigations bPRPs were not detected in secretory granules and saliva from Sm/Sl (21) . In addition to the bPRPs Table II includes three unknown proteins with mass values of 10,434 Ϯ 2, 23,462 Ϯ 3, and 29,415 Ϯ 3 Da that are frequently detectable in the HPLC cluster of bPRPs (5). They were tentatively included in the bPRP family on the basis of their chromatographic properties, absence of absorbance in the near ultraviolet region, and resistance to tryptic digestion. Moreover these proteins are only found in parotid secretion. These are all characteristics of bPRPs.
Protein composition of granules and parotid saliva did not show significant differences except for derivatives of II-2, IB-1, and P-E missing the C-terminal Arg residue (II-2 desArg 75 , IB-1 des-Arg 96 , and P-E des-Arg 61 ) that are present in parotid saliva but not detectable in granules (Table II) . Therefore in agreement with previous investigations, phosphorylation, glycosylation, and convertase cleavage of bPRPs all occur prior to granule storage (28) . Based on analysis of the nucleotide coding regions for P-F, IB-8a, and IB-7 it is likely that these proteins arise by removal of one or more C-terminal residues from precursor proteins (25) . Because P-F and IB-8a are present in parotid granules it appears that this process occurs prior to granule sequestration. No conclusion could be reached with regard to IB-7 because it was only present in one saliva sample. In contrast, the absence of II-2 des-Arg 75 , IB-1 des-Arg 96 , and P-E des-Arg 61 from parotid saliva but the presence in whole saliva indicates that in these instances C-terminal removal takes place after secretion into the mouth. As expected, because of their parotid origin, the relative abundances of bPRPs compared with other saliva proteins are lower in whole saliva, which in addition to parotid saliva contains proteins from other salivary glands.
A number of small peptides (7-21 residues) that potentially could have originated from bPRPs were found in WS but not in parotid secretory granules or parotid saliva (Table III) . These proline-rich peptides were found during an extensive characterization of all the masses detectable in the first 5-12 min of elution during the chromatographic separation of whole saliva. The structures of these peptides were established by 
aa). Residues involved in
PTMs are also shown: ϽQ, N-terminal pyroglutamic acid; S, common phosphorylation sites; *, Ser 17 represents a third minor phosphorylation site. PRP1, PRP2, PIF-s, Db-s are partially cleaved at position Arg 106 (127 for the Db isoform) and generate the four truncated isoforms shown at the bottom of the figure (OE, cleavage site) and P-C peptide (44 residues), common to all the isoforms. The Pa isoform, which has Cys instead of Arg at position 103, is not cleaved, but it is usually present in human saliva as a dimer due to the formation of a disulfide bridge. Some entire or truncated isoforms can partially undergo a carboxypeptidase removal of C-terminal residues (dashed line).
applying selected ion monitoring (SIM) MS/MS strategies and were considered potentially to originate by cleavage of all known acidic and basic PRPs. This possibility was examined using the ExPASy FindPept program. Matches of peptide sequences with PRP sequences were confirmed by manual comparison of the experimental and all theoretical MS/MS spectra using the MS-Product program with ProteinProspector. When possible, MS/MS fragmentation was simultaneously induced on mono-and bicharged ions (Fig. 5) . The monocharged ion ([M ϩ H ϩ ] 1ϩ ) at 874.5 m/z, eluting at about 9.0 min and consistently observed in WS samples, is potentially attributable to more than 100 basic and acidic PRP fragments. A manual comparison of the theoretical MS/MS spectra of all the potential candidates with the experimental MS/MS spectra restricted the possibility to the two peptides GPPPPGKPQ or GPPPPQGKP (the latter is a fragment of aPRP). To discriminate between them an MS 3 experiment was necessary with a secondary SIM centered on internal fragments. Analysis of the MS 3 fragmentation spectra allowed recognition of the internal fragments with m/z values of 477.3 and 380.3 as PPPGK and PPGK, respectively, eliminating any ambiguity. For all the other peptides reported in Table III the first MS/MS fragmentation pattern allowed confirmation of their structures. Table III also shows the number of times the proline-rich fragment is present in the bPRP sequences. Due to the presence of multiple repeats it is impossible to establish from which protein the peptide originated. The presence of these fragments implied a common cleavage at Q2G sites sometimes followed by the removal of one or more C-terminal residues. Cleavage at this site has also been implied in the generation of some fragments of salivary peptides non-covalently bonded to enamel surface (29) .
Histatins-Two Histatins, Histatin 1 and Histatin 3, are encoded by two genes located on chromosome 4q13 (30) . Histatin 1 is a 38-residue peptide, whereas Histatin 3 has a sequence of 32 residues and is very similar to Histatin 1 (30, 31) (Fig. 6 ). Histatin 1 is phosphorylated on Ser 2 (30) , and the tyrosines are partly sulfated (1) .
The masses of Histatins and fragments derived from them, their frequency of occurrence in the granule and saliva preparations, and their concentration as determined semiquantitatively are reported in Table IV . As expected, there were no differences in the relative concentration of Histatin 3 in secretion granules and saliva from the corresponding gland. Moreover the relative concentrations of some of the Histatin 3 fragments (1-25, 1-24, 26 -32, 28 -32, and 29 -32) were the same in granule and saliva samples indicating that they are generated either before or during sequestration into the secretory granules. Although some Histatin 3 fragments were absent or present in very small amounts in secretory granules (Table V) they could be detected in increasing amounts in parotid, Sm/Sl, and whole saliva (Histatin3 1-13, 1-12, 1-11 , 5-13, 5-12, 5-11, 6 -12, 6 -11, 7-13, 7-11, 12-25, 12-24, 13-24, 14 -25, 14 -24, 15-25, and [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Thus it appears that at least part of these fragments is generated after granule release into the salivary gland lumen. The observed peptide pattern supports a proposed sequential processing of Histatin 3 (4).
A comparison of parotid and Sm/Sl secretions based on the ratios of relative abundance of Histatin 3, Histatin 5, and Histatin 6 and total Histatin showed no significant differences, suggesting a comparable activity of the proteinases involved in Histatin 6 and Histatin 5 genesis in both glands (4) . In contrast, the higher concentration of Histatin3 1-13, 1-12, 1-11, 12-25, 12-24, 13-24, 14 -24, and 15-24 in parotid than Sm/Sl saliva shows that parotid saliva is the main source of these fragments in whole saliva. Table II Because the abundance of Histatin 1 plus Histatin 2 was found to be similar in Pr and Sm/Sl saliva, the differences in the ratios were ascribed to an increased secretion of Histatins 3, 5, and 6 from the parotid gland. This is in agreement with results obtained by estimating concentration from UV absorption at 278 nm.
The extent of Histatin 1 phosphorylation can be evaluated by comparing the relative amounts of Histatin 1 and Histatin 2 (non-phosphorylated Histatin 1) in the various samples (Table  VI) . A statistical analysis was done based on the following ratio: ratio ϭ 100 ϫ Histatin 2/(Histatin 1 ϩ Histatin 2).
No significant differences were found between secretory granules, saliva from the same gland and whole saliva. On the contrary, a comparison of parotid and Sm/Sl saliva gave the following result (n ϭ 10): parotid ϭ 10.3 Ϯ 3.1 (mean Ϯ S.D.), Sm/Sl ϭ 19.9 Ϯ 6.4 (mean Ϯ S.D.), p Ͻ 0.0003 (paired t test). On the whole it appears that phosphorylation occurs prior to granule storage as observed on the other salivary proteins and that more extensive phosphorylation occurs in the parotid gland.
This study also confirms the submandibular specificity of Histatin 1 sulfation (Table VI) . Histatin 1 derivatives with a number of sulfates ranging from one to four were clearly detectable both in submandibular secretory granules and in Sm/Sl saliva, but they were not detectable in parotid saliva and secretory granules. The detection of sulfated Histatin 1 in secretory granules in a ratio of relative abundances comparable with those observed in Sm/Sl and whole saliva indicated that Histatin 1 sulfation, similar to phosphorylation, is a PTM occurring prior to granule storage.
Statherin and P-B Peptide-Statherin is an unusual 43-residue phosphopeptide (phosphorylated on Ser 2 and Ser 3 ) found in human saliva (Fig. 7) (32) that is involved in oral cavity calcium ion homeostasis (33) . Its gene (STATH) is localized on chromosome 4q13.3 (Ref. 34; Ensembl ENSG00000126549). Usually P-B peptide (Fig. 7) is included in the bPRP family. However, many characteristics of this peptide suggest a functional relationship with Statherin. Differently from bPRPs, P-B peptide is the product of PROL3 (Ensembl ENSG00000171201) localized on chromosome 4q13.3 very close to the Statherin gene (35) . A similarity analysis performed by the Lalign program showed that the two peptides share more than 47% identity in the last 20 C-terminal residues.
The results of this study, summarized in Table VII , show that Statherin is synthesized in both the parotid and submandibular glands in agreement with previous investigations (2, 36) . It is also apparent that phosphorylation of Statherin occurs before granule storage because the relative concentrations are the same in secretory granules and the corresponding glandular saliva. The vast majority of Statherin is diphosphorylated, and there is no evidence of dephosphorylation after secretion because the relative concentration of variously phosphorylated Statherin is the same in glandular and whole saliva.
TABLE III bPRPs fragments detected only in whole saliva
Potential PRB precursors and the number of repeats of the sequences in each potential precursor have been listed. Ex, experimental; Th, theoretical; S, small; M, medium; L, large. 
Trafficking and PTMs of Human Salivary Peptides
Paired comparison of parotid and Sm/Sl saliva confirmed a slightly higher level of phosphorylation in parotid gland because the relative abundance of monophosphorylated Statherin, although small, was significantly higher in Sm/Sl secretions: ratio ϭ 100 ϫ monophos. Statherin/(monophos. Statherin ϩ 2 ϫ diphos. Statherin). The statistical analysis gave the following results (n ϭ 10): parotid ϭ 0.45 Ϯ 0.29 (mean Ϯ S.D.), Sm/Sl ϭ 1.30 Ϯ 0.77 (mean Ϯ S.D.), p Ͻ 0.02 (paired t test).
SV-1 lacking the C-terminal Phe 43 and Statherin des-Thr 42 -Phe 43 ( Fig. 7) were clearly detectable in parotid and submandibular secretory granules. This suggests that C-terminal removal occurs during maturation of the secretory granules.
The relative abundance of SV-1 was found to be higher in parotid secretion although of low significance: ratio ϭ 100 ϫ SV-1/(all Statherin derivatives). The statistical analysis gave the following results (n ϭ 10): parotid ϭ 21.9 Ϯ 26.6 (mean Ϯ S.D.), Sm/Sl ϭ 4.78 Ϯ 4.44 (mean Ϯ S.D.), p Ͻ 0.05 (paired t test). The N-terminal removal generating Statherin des-Asp 1 is probably an event occurring after granule secretion because this derivative was not detected in granules. Similarly small amounts of P-B des [1] [2] [3] [4] [5] were found in all three types of saliva but not in secretory granules suggesting that also this Nterminal cleavage occurs after secretion.
In contrast to other bPRPs, P-B, being the product of a different gene (35) , is present in both parotid and Sm/Sl saliva. Indeed the relative abundance of P-B is higher in Sm/Sl saliva: ratio ϭ (P-B ϩ derivatives)/(Statherin ϩ derivatives). The statistical analysis gave the following results (n ϭ 10): parotid ϭ 0.52
A similar calculation based on UV absorption at 278 nm showed that this difference is derived from an increased P-B secretion in Sm/Sl glands. Cyclo-Statherin-Q37, recently identified as a Statherin derivative formed by transglutamination of Lys 6 and Gln 37 (37) was detected only and at very small relative abundance in WS samples, confirming that the site of action of transglutaminase 2 is in the oral cavity.
Cystatins-The major salivary Cystatins belong to family 2 of Cystatins (38) comprising Cystatins S, SN, and SA. Cystatin S may be phosphorylated on Ser 3 (Cystatin S1) or diphosphorylated on Ser 1 and Ser 3 (Cystatin S2). The loci producing all Cystatin S are closely clustered on chromosome 20p11.21 together with the loci of Cystatin C and D, named CST1-5. The masses of Cystatins, their frequency of occurrence in the granule and saliva preparations, and their concentration as determined semiquantitatively are reported in Table VIII. All the Cystatins except Cystatins C and D are present in much lower concentrations in parotid than Sm/Sl saliva according to results of other researchers (39) . In contrast to the other salivary proteins investigated, Cystatins were present in very low concentrations or absent from both parotid and Sm/Sl secretory granules. This low relative abundance compared with the high relative abundances observed in Sm/Sl and whole saliva suggests an "S type" Cystatin secretion that is not granule-mediated in agreement with studies that localized the transcript of Cystatin S as well as Cystatin S protein in cytoplasm of serous acinar cells of Sm glands (40) .
Because of the sporadic presence and low abundance of Cystatins S, S1, and S2 in parotid saliva it was not possible to calculate the relative phosphorylation of Cystatin S type in parotid saliva, thereby precluding a comparison with Sm/Sl saliva. In Sm/Sl and whole saliva the relative abundance of Cystatin S1 (monophos.) is 60 -70% of total Cystatin S forms, Cystatin S2 (diphos.) accounts for 20 -30%, and Cystatin S accounts for about 5%.
Cystatin C was found sporadically in parotid, Sm/Sl, and whole saliva, but it was absent from secretory granules, Table III ). RT, retention time; NL, normalization level; i.f., internal fragment.
whereas Cystatin D was not found in any sample. Thus Cystatins C and D may have a different origin than the other salivary Cystatins.
DISCUSSION
The proteomics comparison performed in this study allowed us to establish that salivary peptides and proteins are submitted to a very complex and diversified maturation during and after secretion. The methodological strategy applied was centered on XIC searches of salivary proteins/peptides and their post-translational modification products characterized previously. This XIC approach made it possible to avoid interferences due to sample contamination. Moreover XIC peak area was utilized for semiquantitative measurements of the relative abundances of the peptides and proteins under investigation (41) .
This study was mainly devoted to obtaining information about site of phosphorylation, sulfation, and endo-and exoproteinase cleavages. The method utilized was not suitable for the study of bPRP glycosylation due to the great heterogeneity of the ESI spectra observed for these salivary proteins (5). However, like bPRPs, glycosylated PRPs were only detected in parotid samples.
Phosphorylation and sulfation, after removal of the signal peptides, are the first PTMs occurring probably in the cis-Golgi compartment. A unique kinase confined in the Golgi compartment (Golgi casein kinase) is probably responsible for the phosphorylation of all salivary peptides (20, 42) . From the phosphorylation levels of Histatin 1, aPRPs, and Statherin, the present study shows that the kinase involved is more active in parotid than in Sm/Sl glands. This consistent observation is further support for a unique kinase acting on all salivary peptides. Table IV . peptid., peptidase. the universal sulfate donor adenosine 3Ј-phosphate 5Ј-phosphosulfate to the hydroxyl group of tyrosine residues (43) . However, as we are aware, probably due to the analytical difficulties inherent to the detection of minor amounts of sulfoderivatives, only 37 human sulfated peptides are today reported in Swiss-Prot/TrEMBL, and Histatin 1 represents the second example of a human phosphosulfopeptide detected in vivo. Two different tyrosylprotein sulfotransferases (TPST1 and TPST2) have been identified (44) , and all mammalian cell types studied to date express both. In agreement with our results a TPST has been specifically detected at the level of the Golgi membranes of rat submandibular glands (45) , and Statherin has been recently recognized as one potential substrate of salivary TPST in vitro (46) . However, at the sensitivity level of our apparatus, no sulfo-Statherin was detectable in the samples analyzed. The majority of the consensus sequences observed in the cleavage sites are potentially recognized by enzymes identifiable in the convertase families (47) . Differently from the unique enzymes potentially involved in phosphorylation and sulfation and despite similarities in the consensus sequences observed, the results of this study suggest that the different cleavages of salivary peptides are due to the action of a complex set of endo-and exopeptidases. The convertases responsible for acidic and basic PRPs cleavages act before granule storage. Moreover bPRP convertase is active only in parotid gland, and it is responsible for a complete digestion of the proprotein, whereas aPRP convertase is present in parotid and Sm/Sl glands where it is more active, and it is responsible for a partial cleavage of the proprotein. Two interesting previous studies of Bennick and co-workers (28, 48) addressed the characterization of these proteinases.
On the contrary, the proteinase(s) responsible for the first cleavage of Histatin 3 (Fig. 6 ) seems to work during granule maturation, and until now, nothing was known about its nature. Recently Helmerhorst and Oppenheim (49) proposed an interesting mechanism model explaining the constant ratio of Hst-3 to Hst-5. Also for this proteinase the presence of two Arg residues separated by two amino acid residues seems a mandatory requirement for the enzyme recognition, because Histatin 1, lacking the Arg 25 residue present in Hst-3 ( Fig. 6) , is not cleaved.
The removal of a C-terminal residue by specific carboxypeptidases following a convertase cleavage is an event widespread in many secretory processes (50) . This removal can be observed also during secretion of salivary peptides. Differently from the N-terminal removal of Statherin occurring after granule secretion and the C-terminal removal of some bPRPs occurring before granule storage, the majority of C-terminal removals should occur during granule maturation according to the abundant presence of the truncated products detected in the analysis performed on granules preparations. One of the most relevant removals, in terms of relative abundances, is that involving the C-terminal Arg-25 of Hst-3 fr. 1-25 (Hst-6), generating Hst-3 fr. 1-24 (Hst-5), which is probably linked to the specific antifungal activity of the latter peptide (30, 31) .
After granule secretion Histatin 5 and Histatin 6, but not Histatin 3, are submitted to further cleavages at other minor sites (Fig. 6 ) by the action of unknown endo-and exopeptidases, generating a cascade of fragments. The results of this study indicate that this process occurs mainly during parotid secretion because these fragments were well detectable only in saliva of this gland (and in whole saliva).
Finally other unknown peptidases of endogen or exogen origin are active in the oral cavity. bPRPs, which are their main substrate, are cleaved soon after secretion into the mouth. The main cleavage is at some Q2G sites. This proteinase action generates a lot of small proline-rich peptides originating from repeats present in the parent proteins that were consistently found in almost all the WS samples analyzed. It is interesting to underline that some of these fragments have been detected in a recent study by Vitorino et al. (29) as recurrent non-covalently bound components of the enamel surface. This finding might provide a functional significance to this final bPRP maturation.
Except for phosphorylation, S type Cystatins seem not to undergo further PTMs unlike other salivary peptides. The results of this study show that it would be fruitful to investigate their secretion pathway, which cannot be granule-mediated.
Finally this study can serve as a reference for further clinical proteomics studies using salivary secretion for the diagnosis and prognosis of local and systemic pathologies. It not only confirms that the secretion of salivary peptides follows a well defined pathway where many and well localized enzymatic activities contribute to a complex maturation but also demonstrates qualitative and quantitative differences in the secretion of the main salivary glands. Differences and similarities are summarized in Table IX . They suggest different molecular requirements of different areas of the oral cavity that are a stimulus for further investigations.
* This work was supported by Università di Cagliari, Università Cattolica in Rome, Telethon Grant GGP06170, International Scientific Institute "Paolo VI" (ISI), Ministero dell'Università e della Ricerca, Italian National Research Council (CNR), Regione Sardegna, and Fondazione Banco di Sardegna. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These authors contributed equally to this work. ʈʈ To whom correspondence should be addressed: Istituto di Biochimica e Biochimica Clinica, Facoltà di Medicina, Università Cattolica, Largo F. Vito, I-00168 Roma, Italy. Tel./Fax: 39-06-3053598; E-mail: massimo.castagnola@icrm.cnr.it. 
